{"id":56904,"date":"2026-02-11T22:16:57","date_gmt":"2026-02-11T14:16:57","guid":{"rendered":"https:\/\/flcube.com\/?p=56904"},"modified":"2026-05-14T19:54:52","modified_gmt":"2026-05-14T11:54:52","slug":"takedas-oveporexton-wins-fda-priority-review-for-narcolepsy-type-1-potential-first-orexin-agonist","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56904","title":{"rendered":"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist"},"content":{"rendered":"\n<p><strong>Takeda Pharmaceutical Company Limited<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO:\u202f4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE:\u202fTAK<\/a><\/strong>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has <strong>accepted its New Drug Application (NDA)<\/strong> for <strong>oveporexton (TAK-861)<\/strong> and granted <strong>Priority Review<\/strong> for the treatment of <strong>narcolepsy type 1 (NT1)<\/strong>. The <strong>oral orexin receptor 2 (OX2R)-selective agonist<\/strong>, designed to <strong>restore orexin signaling<\/strong> in patients with <strong>orexin deficiency<\/strong>, could become the <strong>first approved therapy targeting the underlying cause<\/strong> of this <strong>debilitating rare neurological disease<\/strong>, with a <strong>PDUFA goal date in Q3 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Oveporexton (TAK-861) \u2013 Oral OX2R-selective agonist<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td><strong>Priority Review<\/strong> granted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Narcolepsy type 1 (NT1)<\/td><\/tr><tr><td><strong>PDUFA Date<\/strong><\/td><td><strong>Third quarter 2026<\/strong><\/td><\/tr><tr><td><strong>Historical Significance<\/strong><\/td><td>Potential <strong>first approved orexin agonist<\/strong> globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-disease-narcolepsy-type-1-nt1\">Target Disease: Narcolepsy Type 1 (NT1)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>NT1 Profile<\/th><th>Unmet Need<\/th><\/tr><\/thead><tbody><tr><td><strong>Pathophysiology<\/strong><\/td><td><strong>Loss of orexin-producing neurons<\/strong> \u2192 orexin deficiency<\/td><td>Root cause not addressed by current therapies<\/td><\/tr><tr><td><strong>Core Symptoms<\/strong><\/td><td><strong>Excessive daytime sleepiness (EDS)<\/strong> + <strong>cataplexy<\/strong> (sudden muscle tone loss)<\/td><td>Debilitating impact on work, education, social function<\/td><\/tr><tr><td><strong>Current Treatments<\/strong><\/td><td>Wake-promoting agents (modafinil), sodium oxybate, antidepressants<\/td><td><strong>Symptom management only<\/strong>; majority continue experiencing breakthrough symptoms<\/td><\/tr><tr><td><strong>Disease Burden<\/strong><\/td><td>Chronic, lifelong condition with <strong>physical, cognitive, psychosocial effects<\/strong><\/td><td><strong>No disease-modifying or replacement therapies available<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-3-firstlight-amp-radiantlight-studies\">Clinical Evidence: Phase 3 FirstLight &amp; RadiantLight Studies<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Design<\/th><th>Key Endpoints<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>FirstLight (TAK-861-3001)<\/strong><\/td><td>Global Phase 3<\/td><td>EDS improvement; cataplexy reduction<\/td><td>Primary efficacy validation<\/td><\/tr><tr><td><strong>RadiantLight (TAK-861-3002)<\/strong><\/td><td>Global Phase 3<\/td><td>Sustained symptom control; safety profile<\/td><td>Long-term durability and tolerability<\/td><\/tr><tr><td><strong>Combined Package<\/strong><\/td><td>Comprehensive NDA submission<\/td><td><strong>Restoration of orexin signaling<\/strong><\/td><td><strong>First disease-targeting mechanism<\/strong> in NT1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-competitive-differentiation\">Mechanism of Action &amp; Competitive Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Oveporexton Approach<\/th><th>Current Standard of Care<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td><strong>Orexin receptor 2 (OX2R)-selective agonist<\/strong><\/td><td>Symptomatic wake-promotion or GABA-B modulation<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td><strong>Restores orexin signaling<\/strong> to address <strong>underlying deficiency<\/strong><\/td><td>Mask symptoms without correcting pathophysiology<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td><strong>Oral, once-daily<\/strong><\/td><td>Sodium oxybate requires twice-nightly dosing; strict REM sleep protocol<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td><strong>First-in-class orexin agonist<\/strong><\/td><td>Incremental improvements to decades-old mechanisms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Orphan Disease Premium<\/strong><\/td><td>NT1 affects <strong>~1 in 2,000 individuals<\/strong>; orphan drug designation enables <strong>pricing power and market exclusivity<\/strong><\/td><\/tr><tr><td><strong>Takeda Rare Disease Focus<\/strong><\/td><td>Aligns with <strong>Takeda&#8217;s 2025 strategic pivot<\/strong> to <strong>gastroenterology, rare diseases, and plasma-derived therapies<\/strong>; reduces reliance on mature products<\/td><\/tr><tr><td><strong>First-Mover Advantage<\/strong><\/td><td><strong>No competing orexin agonists in late-stage development<\/strong>; 3-5 year competitive moat if approved<\/td><\/tr><tr><td><strong>Expansion Potential<\/strong><\/td><td>OX2R mechanism applicable to <strong>narcolepsy type 2<\/strong> (NT2), <strong>idiopathic hypersomnia<\/strong>, and <strong>other sleep-wake disorders<\/strong><\/td><\/tr><tr><td><strong>Global Launch Readiness<\/strong><\/td><td>Takeda&#8217;s <strong>Japan\/US dual headquarters<\/strong> enables <strong>simultaneous regulatory submissions<\/strong> (PMDA filing anticipated post-FDA action)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding oveporexton FDA approval timelines, commercial launch success in narcolepsy type 1, and Takeda&#8217;s rare disease franchise expansion. Actual results may differ due to FDA advisory committee recommendations, pricing and reimbursement negotiations, and physician adoption curves for novel sleep disorder mechanisms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO:\u202f4502, NYSE:\u202fTAK) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,874,80,24,345,1141],"class_list":["post-56904","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-market-approval-filings","tag-nyse-tak","tag-priority-reviews","tag-rare-orphan-disease-drugs","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO:\u202f4502, NYSE:\u202fTAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for oveporexton (TAK-861) and granted Priority Review for the treatment of narcolepsy type 1 (NT1). The oral orexin receptor 2 (OX2R)-selective agonist, designed to restore orexin signaling in patients with orexin deficiency, could become the first approved therapy targeting the underlying cause of this debilitating rare neurological disease, with a PDUFA goal date in Q3 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56904\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO:\u202f4502, NYSE:\u202fTAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for oveporexton (TAK-861) and granted Priority Review for the treatment of narcolepsy type 1 (NT1). The oral orexin receptor 2 (OX2R)-selective agonist, designed to restore orexin signaling in patients with orexin deficiency, could become the first approved therapy targeting the underlying cause of this debilitating rare neurological disease, with a PDUFA goal date in Q3 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56904\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T14:16:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T11:54:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56904#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56904\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist\",\"datePublished\":\"2026-02-11T14:16:57+00:00\",\"dateModified\":\"2026-05-14T11:54:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56904\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Market approval filings\",\"NYSE: TAK\",\"Priority reviews\",\"Rare \\\/ orphan disease drugs\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56904#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56904\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56904\",\"name\":\"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-11T14:16:57+00:00\",\"dateModified\":\"2026-05-14T11:54:52+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO:\u202f4502, NYSE:\u202fTAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for oveporexton (TAK-861) and granted Priority Review for the treatment of narcolepsy type 1 (NT1). The oral orexin receptor 2 (OX2R)-selective agonist, designed to restore orexin signaling in patients with orexin deficiency, could become the first approved therapy targeting the underlying cause of this debilitating rare neurological disease, with a PDUFA goal date in Q3 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56904#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56904\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56904#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO:\u202f4502, NYSE:\u202fTAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for oveporexton (TAK-861) and granted Priority Review for the treatment of narcolepsy type 1 (NT1). The oral orexin receptor 2 (OX2R)-selective agonist, designed to restore orexin signaling in patients with orexin deficiency, could become the first approved therapy targeting the underlying cause of this debilitating rare neurological disease, with a PDUFA goal date in Q3 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56904","og_locale":"en_US","og_type":"article","og_title":"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist","og_description":"Takeda Pharmaceutical Company Limited (TYO:\u202f4502, NYSE:\u202fTAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for oveporexton (TAK-861) and granted Priority Review for the treatment of narcolepsy type 1 (NT1). The oral orexin receptor 2 (OX2R)-selective agonist, designed to restore orexin signaling in patients with orexin deficiency, could become the first approved therapy targeting the underlying cause of this debilitating rare neurological disease, with a PDUFA goal date in Q3 2026.","og_url":"https:\/\/flcube.com\/?p=56904","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T14:16:57+00:00","article_modified_time":"2026-05-14T11:54:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56904#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56904"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist","datePublished":"2026-02-11T14:16:57+00:00","dateModified":"2026-05-14T11:54:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56904"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Market approval filings","NYSE: TAK","Priority reviews","Rare \/ orphan disease drugs","Takeda","TYO: 4502"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56904#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56904","url":"https:\/\/flcube.com\/?p=56904","name":"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-11T14:16:57+00:00","dateModified":"2026-05-14T11:54:52+00:00","description":"Takeda Pharmaceutical Company Limited (TYO:\u202f4502, NYSE:\u202fTAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for oveporexton (TAK-861) and granted Priority Review for the treatment of narcolepsy type 1 (NT1). The oral orexin receptor 2 (OX2R)-selective agonist, designed to restore orexin signaling in patients with orexin deficiency, could become the first approved therapy targeting the underlying cause of this debilitating rare neurological disease, with a PDUFA goal date in Q3 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56904#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56904"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56904#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda\u2019s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56904"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56904\/revisions"}],"predecessor-version":[{"id":56905,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56904\/revisions\/56905"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}